Meet the management of two innovative start-ups, one in the management of general anesthesia, the other in the treatment of Cancer:
Medsteer is a company developing an innovative medical device for anesthesiologists in the operating room. The EasyTIVA system, thanks to a patented algorithm based on cerebral activity, allows to regulate in real time the depth of the general anesthesia of the patient and to reduce the post-operative side effects. Patients wake up quickly and comfortably.
NH TherAguix is a pharmaceutical company developing innovative nanomedicine that improves the effectiveness of radiotherapy and reduces side effects without changing clinical practice. Its AGuIX® drug, in clinical phase 1, is a non-invasive, personalized solution that improves cancer imaging and treatment.
Tuesday 27th June 2017, Paris 8ème
6.45 pm : OPENING
7 pm-7.45 pm CONFERENCE Medsteer
8 pm -8.45 pm CONFERENCE NH TherAguix
8.30 pm – 10.30 pm COCKTAIL
Further discussions with the management
Thierry CHAZOT, MD, Co-founder, R & D, President
Nicolas CHOUSSAT, MS, Co-founder, Operations, CEO
Ngai LIU, MD PhD, Co-founder, R & D, Medical Director
Team NH TherAguix:
Géraldine LE DUC, President and co-founder of NH TherAguix
Sandrine DUFORT, Head of clinical trials and preclinical R & D
François LUX, PhD in Chemistry, PI manager and production and preclinical R & D
You can read more about Medsteer and NH TherAguix on the PRE IPO platform of Invest Securities Group.